APP下载

自拟方联合靶向药物对晚期非小细胞肺癌的治疗效果与优势分析

2021-12-13刘长顺

婚育与健康 2021年21期

刘长顺

【摘 要】目的:分析在晚期非小细胞肺癌患者临床治疗中采用自拟方以及靶向药物治疗的临床疗效。方法:将本院于2019年2月至2021年5月接收治疗的非小细胞肺癌晚期患者共42例按照随机数字表法分为观察组和对照组,对比分析临床疗效、细胞免疫指标变化。结果:治疗后观察组疗效明显更高;观察组CD3、CD4、CD4/CD8明显更高,对比统计学差异明显(P<0.05)。结论:在非小细胞肺癌晚期患者治疗中采用本院自拟方及靶向药物治疗将更有利于改善患者临床指标。

【关键词】自拟方;靶向药物;非小细胞肺癌;晚期

Therapeutic effect and advantage analysis of self-made for mulacombined with targeted drugs on advanced non-small cell lung cancer

Liu Changshun

Jiaxing Ivy Hospital for the Elderly, Zhejiang Jiaxing 314000,China

【Abstract】Objective: To analyze the clinical efficacy of self-designed prescriptions and targeted drugs in the clinical treatment of patients with advanced non-small cell lung cancer. Methods: A total of 42 advanced non-small cell lung cancer patients treated in our hospital from February 2019 to May 2021 were divided into observation group and control group according to random number table method, and the clinical efficacy and changes of cellular immune indexes were compared and analyzed. Results: The curative effect of observation group was significantly higher after treatment.CD3,CD4 and CD4/CD8 were significantly higher in the observation group, and the difference was statistically significant (P<0.05).Conclusion:In the treatment of advanced non-small cell lung cancer patients, the use of self-designed prescriptions and targeted drugsin our hospital will be more conducive to improve the clinical indicators of patients.

【Key?Words】Self-designedprescription; Targeted drugs; Non-small cell lung cancer; Advanced

非小细胞肺癌是一种常见的肺部恶性腫瘤,其发病位置主要与其转移情况相关,显微镜下可见该类恶性肿瘤核异形、细胞较大、胞浆更为丰富。晚期非小细胞肺癌可出现癌细胞转移等情况,病情逐渐加重,为患者的临床治疗增加了困难,晚期生存率普遍较低,在这样的前提下,如何有效提高患者治疗疗效是临床关注的重点[1-2]。对此,本次研究针对本院收治的非小细胞肺癌晚期患者采取本院自拟方联合西药靶向药物治疗,旨在分析其临床价值,详见下文所示。

1 资料和方法

1.1 一般资料

将本院于2019年2月至2021年5月接收治疗的非小细胞肺癌晚期患者共42例按照随机数字表法分为观察组和对照组。观察组21例,男性13例,女性8例,年龄50岁~84岁,平均年龄(66.33±2.14)岁;对照组21例,男性11例,女性10例,年龄52岁~82岁,平均年龄(66.32±2.12)岁;两组患者年龄等资料对比并无明显差异(P>0.05)。

1.2 方法

1.2.1 对照组患者采取阿美替尼(生产厂家:江苏豪森药业集团有限公司;批准文号:国药准字H20200004;规格:55mg)治疗,1次/ d ,每次110mg治疗,直至出现疾病治疗进展或不可耐受毒性。

登录APP查看全文